PBAC fast-tracks molnupiravir for streamlined authority listing
The federal Department of Health has offered advice on splitting the capsules to make an oral solution
GPs are a step closer to prescribing COVID-19 antivirals on the PBS after a fast-tracked recommendation on Friday for the listing of molnupiravir.
Molnupiravir (Lagevrio from Merck Sharp & Dohme) and nirmatrelvir–ritonavir (Paxlovid from Pfizer) have been available through the National Medical Stockpile for about two weeks, with officials warning PBS listings might be “months away”.
However, on Friday, the PBAC made a positive recommendation for Lagevrio to receive a streamlined authority listing for patients with mild-to-moderate COVID-19 and the following eligibility criteria:
The committee said eligibility details were still being worked out but not having at least two doses of a COVID-19 vaccine would count as one risk factor.
